The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance

Minh Ngoc Duong _, Aline Geneste, Frederique Fallone, Xia Li, Charles Dumontet and Catherine Muller

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57622-57641. https://doi.org/10.18632/oncotarget.18038

Metrics: PDF 3449 views  |   HTML 7808 views  |   ?  


Minh Ngoc Duong1, Aline Geneste2, Frederique Fallone3, Xia Li3, Charles Dumontet2,4 and Catherine Muller3

1Department of Oncology/CHUV-UNIL, Biopole 3, Epalinges, Switzerland

2Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052/CNRS 5286, Lyon, France

3Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France

4Hospices Civils de Lyon, Lyon, France

Correspondence to:

Minh Ngoc Duong, email: [email protected]

Keywords: adipocytes, adipose tissue, cancer progression, invasion, resistance

Received: December 06, 2016     Accepted: May 08, 2017     Published: May 20, 2017


Growing evidence has raised the important roles of adipocytes as an active player in the tumor microenvironment. In many tumors adipocytes are in close contact with cancer cells. They secrete various factors that can mediate local and systemic effects. The adipocyte-cancer cell crosstalk leads to phenotypical and functional changes of both cell types, which can further enhance tumor progression. Moreover, obesity, which is associated with an increase in adipose mass and an alteration of adipose tissue, has been established as a risk factor for cancer incidence and cancer-related mortality. In this review, we summarize the mechanisms of the adipocyte-cancer cell crosstalk in both obese and lean conditions as well as its impact on cancer cell growth, local invasion, metastatic spread and resistance to treatments. Better characterization of cancer-associated adipocytes and the key molecular events in the adipocyte-cancer cell crosstalk will provide insights into tumor biology and suggest efficient therapeutic opportunities.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18038